<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Medebound HEALTH]]></title><description><![CDATA[Medebound HEALTH]]></description><link>https://www.medeboundhealth.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Wed, 06 May 2026 13:59:15 GMT</lastBuildDate><atom:link href="https://www.medeboundhealth.com/ar/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Synovial Sarcoma in the U.S.:  World's First T-Cell Receptor Gene Therapy Tecelra — A Historic Breakthrough]]></title><description><![CDATA[Synovial sarcoma is a rare, aggressive cancer with limited treatment options. Tecelra, the first T-cell receptor (TCR) gene therapy approved in the U.S., marks a major breakthrough by engineering patients’ T-cells to target tumor antigens. It has shown promising responses in advanced cases, offering new hope and advancing precision cancer therapy.]]></description><link>https://www.medeboundhealth.com/post/synovial-sarcoma-afami-cel-tecelra-fda-usa</link><guid isPermaLink="false">69e24c9343fd38a1bb6f7197</guid><category><![CDATA[Disease]]></category><pubDate>Fri, 17 Apr 2026 15:06:59 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_37167e33f53f4181bda025e399b6f650~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Rhabdomyosarcoma in the U.S.:    The World's Most Advanced Trials for This Aggressive Pediatric Sarcoma]]></title><description><![CDATA[<h2>What Is Rhabdomyosarcoma?</h2><p><strong>Rhabdomyosarcoma (RMS)</strong> is the <strong>most common soft tissue sarcoma in children and adolescents</strong>, accounting for approximately <strong>3%–4% of all childhood cancers</strong> and approximately <strong>350 new cases per year</strong> in the United States. RMS arises from <strong>primitive mesenchymal cells</strong> that normally give rise to skeletal muscle, though it can occur in sites that lack skeletal muscle (e.g., bladder,...]]></description><link>https://www.medeboundhealth.com/post/rhabdomyosarcoma-treatment-usa-pediatric-clinical-trials</link><guid isPermaLink="false">69e24c920c8d230c9e8d11e1</guid><category><![CDATA[Disease]]></category><pubDate>Fri, 17 Apr 2026 15:06:58 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_2d521e1e055740b5bf71c0ce129e82d5~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Leiomyosarcoma in the US:  Landmark LMS04 Trial Proves Doxorubicin+Trabectedin Extends Survival to 33 Months+B6B7]]></title><description><![CDATA[<h2>What Is Leiomyosarcoma?</h2><p><strong>Leiomyosarcoma (LMS)</strong> is the <strong>second most common soft tissue sarcoma</strong>, arising from <strong>smooth muscle cells</strong>. It can develop virtually anywhere in the body where smooth muscle is present — most commonly the <strong>uterus, retroperitoneum, and major blood vessel walls</strong>. LMS is broadly categorized into two major subtypes: <strong>uterine LMS (uLMS)</strong> and <strong>soft tissue / retroperitoneal LMS...]]></description><link>https://www.medeboundhealth.com/post/leiomyosarcoma-treatment-usa-doxorubicin-trabectedin-lms04</link><guid isPermaLink="false">69e24c91724c2c08e3305be5</guid><category><![CDATA[Disease]]></category><pubDate>Fri, 17 Apr 2026 15:06:57 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_c7df5401298d467a8a67ab8518a8418b~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Liposarcoma in the U.S. FDA-Approved Eribulin and Trabectedin Plus an Emerging MDM2 Inhibitor Pipeline Offer New Hope]]></title><description><![CDATA[<h2>What Is Liposarcoma?</h2><p><strong>Liposarcoma</strong> is the most common subtype of soft tissue sarcoma, arising from <strong>adipose (fat) tissue</strong>. It accounts for approximately <strong>20% of all soft tissue sarcomas</strong> and most frequently occurs in the <strong>retroperitoneum and extremities</strong>. Liposarcoma encompasses five major subtypes with markedly different biologies: <strong>well-differentiated liposarcoma (WDLPS)</strong> and <strong>dedifferentiated...]]></description><link>https://www.medeboundhealth.com/post/liposarcoma-treatment-usa-eribulin-mdm2-inhibitor</link><guid isPermaLink="false">69e24c90a96d49e56ebd3b1d</guid><category><![CDATA[Disease]]></category><pubDate>Fri, 17 Apr 2026 15:06:57 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_c29737a5c10445fcbfd9d21a0773da7f~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Osteosarcoma in the U.S. : Now Adding Cabozantinib to Standard Chemo to Break a Decades-Long Stalemate]]></title><description><![CDATA[<h2>What Is Osteosarcoma?</h2><p><strong>Osteosarcoma</strong> is the most common primary malignant bone tumor, accounting for approximately <strong>800–900 new cases annually</strong> in the United States. It primarily affects <strong>children, adolescents, and young adults</strong> (peak incidence in the second decade of life), with a second smaller peak in patients over 65. The tumor most frequently arises in the <strong>metaphysis of long bones</strong> — particularly the distal femur,...]]></description><link>https://www.medeboundhealth.com/post/osteosarcoma-treatment-usa-cabozantinib-regorafenib</link><guid isPermaLink="false">69e24c90878f146d603f7c86</guid><category><![CDATA[Disease]]></category><pubDate>Fri, 17 Apr 2026 15:06:56 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_dad8a456295748d0bf7fc809a352fc3b~mv2.jpeg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>medebound</dc:creator></item><item><title><![CDATA[Malignant Mesothelioma Treatment in the US: Dual Immunotherapy Breaks a 16-Year Stalemate, Extending Survival to 18 Months]]></title><description><![CDATA[</style><h2>What Is Malignant Mesothelioma?</h2><p>Malignant mesothelioma is a cancer arising from the mesothelial cells lining the pleura, peritoneum, pericardium, or tunica vaginalis testis. In the United States, its incidence is approximately 0.6–1.0 per 100,000, with about 2,500–3,000 new diagnoses annually, making it one of the more prevalent rare solid tumors. The primary cause is prior asbestos exposure, with a latency period of 20–50 years; most patients are therefore over 60 at the...]]></description><link>https://www.medeboundhealth.com/post/malignant-mesothelioma-dual-immunotherapy-usa</link><guid isPermaLink="false">69e1365994a0b98ef05f494f</guid><category><![CDATA[Disease]]></category><pubDate>Thu, 16 Apr 2026 19:19:54 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/a02a7d9e6ea54e0985c11cc536f79e83.jpg/v1/fit/w_960,h_675,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>medebound</dc:creator></item><item><title><![CDATA[Anal Canal Cancer in the US: Finally Has an Immunotherapy What FDA Approval of Zynyz in 2025 Mean for Patients?]]></title><description><![CDATA[</style><h2>What Is Squamous Cell Carcinoma of the Anal Canal?</h2><p>Squamous cell carcinoma of the anal canal (SCAC) is a malignancy arising from the epithelium of the anal canal. In the United States, its incidence is approximately 2.0 per 100,000, with about 10,000 new diagnoses annually — making it one of the more prevalent rare cancers. The primary cause is persistent infection with human papillomavirus (HPV, particularly HPV-16/18); high-risk groups include HIV-positive individuals,...]]></description><link>https://www.medeboundhealth.com/post/anal-canal-cancer-zynyz-fda-approval-usa</link><guid isPermaLink="false">69e1365994a0b98ef05f494b</guid><category><![CDATA[Disease]]></category><pubDate>Thu, 16 Apr 2026 19:19:53 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/a4d56202e0b84fe9ad98d9ba859b1ef2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Metaplastic Breast Cancer in the U.S.: When Chemotherapy Fails, These Breakthrough Options Are Now Available ]]></title><description><![CDATA[</style><h2>What Is Squamous Cell Carcinoma of the Anal Canal?</h2><p>Squamous cell carcinoma of the anal canal (SCAC) is a malignancy arising from the epithelium of the anal canal. In the United States, its incidence is approximately 2.0 per 100,000, with about 10,000 new diagnoses annually — making it one of the more prevalent rare cancers. The primary cause is persistent infection with human papillomavirus (HPV, particularly HPV-16/18); high-risk groups include HIV-positive individuals,...]]></description><link>https://www.medeboundhealth.com/post/metaplastic-breast-cancer-treatment-usa</link><guid isPermaLink="false">69e13658c4c584cedb054982</guid><category><![CDATA[Disease]]></category><pubDate>Thu, 16 Apr 2026 19:19:52 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_dad01c8b7c164ca1898fcf7fb6e30aab~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>medebound</dc:creator></item><item><title><![CDATA[恶性间皮瘤：美国双免疫疗法打破16年僵局，中位生存期提升至18个月_美联医邦]]></title><link>https://www.medeboundhealth.com/zh/post/exin-jianpiliu</link><guid isPermaLink="false">69e036c047c3def1fff17b2f</guid><pubDate>Thu, 16 Apr 2026 01:09:20 GMT</pubDate><dc:creator>medebound</dc:creator></item><item><title><![CDATA[晚期肛管癌终于有了免疫疗法：2025-26年美国Zynyz获批意味着什么？_美联医邦]]></title><link>https://www.medeboundhealth.com/zh/post/gang-guan-ai</link><guid isPermaLink="false">69e036bfc0d279b375a7d0f8</guid><pubDate>Thu, 16 Apr 2026 01:09:19 GMT</pubDate><dc:creator>medebound</dc:creator></item><item><title><![CDATA[化生性乳腺癌患者在美国还有这些突破性选择_美联医邦]]></title><link>https://www.medeboundhealth.com/zh/post/hua-sheng-ruxian-ai</link><guid isPermaLink="false">69e036bfc0d279b375a7d0f5</guid><pubDate>Thu, 16 Apr 2026 01:09:19 GMT</pubDate><dc:creator>medebound</dc:creator></item><item><title><![CDATA[Top Telehealth Platforms for Global Patients with Critical Disease: Access Top 1% US Specialists (2026)]]></title><description><![CDATA[Serious illness often brings with it a difficult reality: medical decisions must be made quickly, yet the most experienced specialists may be located thousands of miles away. For patients facing rare cancers, complex diagnoses, or life-threatening diseases , access to physicians who treat these conditions every day can significantly influence treatment strategy. In the past, obtaining such expertise almost always required international travel to major academic hospitals in the United States...]]></description><link>https://www.medeboundhealth.com/post/top-telehealth-platforms-for-global-patients-with-critical-disease-to-usa-specialist</link><guid isPermaLink="false">69aa1a00b5dd058733478e7e</guid><pubDate>Fri, 06 Mar 2026 01:05:10 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_7c78f1ad71f344989fdf80d30c8bede9~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Best Hospitals for Breast Cancer in the US (2025-2026): How to Choose the Right Center and What to Do When Access Is Unclear]]></title><description><![CDATA[Author: Medical Editor Sue Table of content: If you received a breast cancer diagnosis, start here What "best" really means for breast cancer care, and how we rank hospitals Top 5 U.S. Hospitals for Breast Cancer (2025–2026) When a Top Hospital Is Identified But Access Is Unclear A Structured Pathway Families Use After Identifying Top Hospitals Medebound HEALTH: A Structured Remote Review Option Case of an Asian Metaplastic Breast Cancer Patient Receiving Remote Video Consultation with U.S....]]></description><link>https://www.medeboundhealth.com/post/best-hospitals-for-breast-cancer-in-the-us</link><guid isPermaLink="false">69a083592f9cd66cc9412b7c</guid><category><![CDATA[Blog]]></category><pubDate>Thu, 26 Feb 2026 18:12:57 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/b44926_675bab721107481596c15bcdb0365411~mv2.png/v1/fit/w_755,h_467,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Seeking a Second Opinion for Sarcoma: A Practical Guide (2026) When Access to a Major Sarcoma Center Is Delayed or Difficult]]></title><description><![CDATA[A sarcoma diagnosis often brings urgent treatment decisions that may permanently affect future options. This article outlines when a structured U.S. second opinion may be appropriate, what it evaluates, and how patients can obtain independent expert review when access to major cancer centers is delayed. The goal is clarity before irreversible steps are taken.]]></description><link>https://www.medeboundhealth.com/post/sarcoma-second-opinion</link><guid isPermaLink="false">699dd87fe6cf3604ca33c17a</guid><category><![CDATA[Blog]]></category><pubDate>Tue, 24 Feb 2026 17:43:20 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_98232a492d12438e971d259a42080013~mv2.avif/v1/fit/w_925,h_643,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Best Hospital for Prostate Cancer in USA: 2026 Guide for Patients and Families]]></title><description><![CDATA[Author: Medical Editor Sue Table of contents: Evaluating a Prostate Cancer Program: Key Clinical Criteria Recognized U.S. Centers for Prostate Cancer Care Aligning Center Selection With Clinical Stage and Goals Questions to Raise With Any Program Before Proceeding 3 Ways to Seek an Expert Opinion on Prostate Cancer Practical Considerations When Access to a Major Center Is Delayed or Difficult If travel or waitlists are a problem, a remote second opinion can still add clarity Identifying an...]]></description><link>https://www.medeboundhealth.com/post/best-hospital-for-prostate-cancer-in-usa</link><guid isPermaLink="false">6997e7d74c11d313e899fc71</guid><pubDate>Fri, 20 Feb 2026 18:31:47 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8c8800_52e8c295a16d4f218ec63d05226d6daf~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Online Second Opinion for Breast Cancer: Best U.S. Hospitals without Traveling and Wait]]></title><description><![CDATA[Author: Medical Editor Sue Reading Time: 8 Minutes Table of Contents: Before You Commit: Four Questions to Ask Yourself When a Second Opinion Can be Valuable for Your Plan Your Options for a Breast Cancer Second Opinion Why Experience and High-Volume Centers Matter in Breast Cancer Top U.S. Institutions Patients Look to for Breast Cancer Expertise Travel, Cost, and Scheduling Barriers to In-Person Second Opinions A Structured Remote Second Opinion Through Medebound HEALTH How One Consultation...]]></description><link>https://www.medeboundhealth.com/post/breast-cancer-second-opinion</link><guid isPermaLink="false">69969bb1f797687350e7b9da</guid><pubDate>Thu, 19 Feb 2026 16:25:54 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_a4de3e9b2e1e45fcb9704be046fdf357~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Prostate Cancer Second Opinion in 2026: Comparing Treatment Strategies and Your Real Options]]></title><description><![CDATA[Author: Medical Editor Sue Reading Time: 8 Minutes Table of Contents: Why a Prostate Cancer Second Opinion Matters The Questions Patients Rarely Say Out Loud — but Are Deciding Everything Your Options for a Prostate Cancer Second Opinion Why Experience and High-Volume Centers Such as MD Anderson and Memorial Sloan Kettering Matter More Medebound HEALTH: A Structured Approach to U.S. Expert Review How Medebound HEALTH Connects Patients to Top U.S. Cancer Specialist How the Process Works...]]></description><link>https://www.medeboundhealth.com/post/prostate-cancer-second-opinion</link><guid isPermaLink="false">698096d399fa9e70ea5f4e7f</guid><category><![CDATA[Blog]]></category><pubDate>Mon, 02 Feb 2026 13:11:27 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/546538_7594e9d4aef446ec89dabc0001579902~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[Medical Travel to China 2026: What Do You Need to Know]]></title><description><![CDATA[Fed up with sky-high medical costs and endless waits? 2026’s Medical Travel to China guide: unbeatable ChinaMedical value, viral influencer experiences, two booking ways, and Medebound’s MedicalTourismChina expertise for a seamless trip!]]></description><link>https://www.medeboundhealth.com/post/medical-travel-to-china-2026</link><guid isPermaLink="false">69772a10e611fcb48794d58e</guid><pubDate>Mon, 26 Jan 2026 10:39:56 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/b44926_73116a778d024dbf991170acd247f910~mv2.png/v1/fit/w_596,h_373,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>medebound</dc:creator></item><item><title><![CDATA[Lung Cancer Second Opinion 2026: Cost, Options &#38; How to Access Physicians Affiliated to U.S. Top 5 Cancer Centers]]></title><description><![CDATA[Author: Medical Editor Sue Reading Time:  6 minutes Table of Contents: Introduction: Why a Second Opinion Matters More Than Ever Why You Need a Lung Cancer Second Opinion Now Real Story: Stage IV Non-Small Cell Lung Cancer, Video Consultation Leading to Comprehensive Treatment and Tumor Shrinkage How to Choose the Right Specialist for a Lung Cancer Second Opinion Preparing Your Medical Records for an Accurate Review Your Options for Getting a Lung Cancer Second Opinion How Medebound Health...]]></description><link>https://www.medeboundhealth.com/post/lung-cancer-second-opinion-2026-cost-options-how-to-access</link><guid isPermaLink="false">697253a39f5bcea2284f432d</guid><pubDate>Thu, 22 Jan 2026 18:48:22 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/710a3e_b55255bd110943dd92aacb83e44b9fa0~mv2.avif/v1/fit/w_925,h_626,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item><item><title><![CDATA[MSKCC Second Opinion Paused? How to Secure a Second Opinion from Top 5 U.S. Cancer Specialist 2026]]></title><description><![CDATA[Published by:  Medebound HEALTH Reading Time:  6 minutes Table of Content: Why a Second Opinion Matters in Cancer Care What Happened to MSKCC’s Remote Second Opinion Program? If MSKCC Paused Its Remote Second Opinion Right Now, What Can You Do? Why This Matters for YOU Here’s how it works: What to Do Next Contact Us to Get Started Cancer patients often seek second opinions to confirm diagnoses, explore treatment options, and gain peace of mind. Memorial Sloan Kettering Cancer Center (MSKCC)...]]></description><link>https://www.medeboundhealth.com/post/mskcc-second-opinion-pause-how-to-secure-a-second-opinion-from-doctors-at-memorial-sloan-and-other</link><guid isPermaLink="false">69482f8c93dd8b221e6c2f98</guid><category><![CDATA[Blog]]></category><pubDate>Sun, 21 Dec 2025 18:35:03 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/49cf2d_4d932d1d358b43cd859332ea333eb016~mv2.png/v1/fit/w_1000,h_768,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Medebound HEALTH</dc:creator></item></channel></rss>